PromarkerD licence agreement announcements are ongoing and can come at anytime. May not move the SP significantly until revenue kicks in but it does strengthen the company's future and value.
The results from the Phase 2 Janssen study if shown to be beneficial for Janssen will be a huge catalyst for PIQ. Not only will the PromarkeD test support Janssen's drug but also other companies diabetes drugs. Big Pharma will promote the test.
Results getting closer, was projected by end of the year.
Ann: Middle East is next market for PromarkerD immunoassay test, page-32
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.005(1.27%) |
Mkt cap ! $63.83M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 39.5¢ | 37.5¢ | $70.18K | 183.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 76292 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 24754 | 2 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |